Glioblastoma multiforme: Effect of hypoxia and hypoxia-inducible factors on therapeutic approaches (Review)

WEN-JUAN HUANG, WEI-WEI CHEN and XIA ZHANG

Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China

Received May 5, 2016; Accepted July 27, 2016

DOI: 10.3892/ol.2016.4952

Abstract. Central nervous system-based cancers have a much higher mortality rate with the 2016 estimates at 6.4 for incidence and 4.3 for deaths per 100,000 individuals. Grade IV astrocytomas, known as glioblastomas are highly aggressive and show a high proliferation index, diffused infiltration, angiogenesis, microvascular proliferation and pleomorphic vessels, resistance to apoptosis, and pseudopalisading necrosis. Extensive hypoxic regions in glioblastomas contribute to the highly malignant phenotype of these tumors. Hypoxic regions of glioblastoma exacerbate the prognosis and clinical outcomes of the patients as hypoxic tumor cells are resistant to chemo- and radiation therapy and are also protected by the malfunctional vasculature that developed due to hypoxia. Predominantly, hypoxia-inducible factor-1α, vascular endothelial growth factor (VEGF)/VEGF receptor, transforming growth factor-β, epidermal growth factor receptor and PI3 kinase/Akt signaling systems are involved in tumor progression and growth. Glioblastomas are predominantly glycolytic and hypoxia-induced factors are useful in the metabolic reprogramming of these tumors. Abnormal vessel formation is crucial in generating pseudopalisading necrosis regions that protect cancer stem cells residing in that region from therapeutic agents and this facilitates the cancer stem cell niche to expand and contribute to cell proliferation and tumor growth. Therapeutic approaches that target hypoxia-induced factors, such as use of the monoclonal antibody against VEGF, bevacizumab, have been useful only in stabilizing the disease but failed to increase overall survival. Hypoxia-activated TH-302, a nitroimidazole prodrug of cytotoxin bromo-isophosphoramide mustard, appears to be more attractive due to its better beneficial effects in glioblastoma patients. A better understanding of the hypoxia-mediated protection of glioblastoma cells is required for developing more effective therapeutics.

Contents

1. Introduction
2. Significance of hypoxia in development of glioblastoma
3. Hypoxia, growth factors and tumor angiogenesis
4. Significance of abnormal vessel formation in glioblastoma
5. Hypoxia and glioblastoma stem cells
6. Therapeutic implications
7. Conclusions

1. Introduction

Central nervous system (CNS)-based cancers account for approximately 1.4% of all cancers worldwide and account for proportionally more deaths, i.e., 2.7% among cancer-related mortalities (1). Estimates for incidence of CNS cancer in 2016 were 6.4/100,000 individuals and for deaths this was 4.3/100,000 (2). Notably, of the many types of cells in CNS, most of the malignant tumors in brain originate from astrocytes. There are four distinct types of astrocytomas, classified on the basis of microscopic characteristics, grades (I-IV). Only the relatively rare grade I astrocytomas are curable while the other gliomas are incurable. Although grade III and IV gliomas are considered high-grade gliomas, only grade IV glioma is commonly known as glioblastoma multiforme. Glioblastomas show a high mitotic/proliferation index, diffused infiltration, angiogenesis, microvascular proliferation and pleomorphic vessel resistance to apoptosis, nuclear atypia, and pseudopalisading necrosis (3,4). Gliomas progress with time from the time of diagnosis to aggressiveness and approximately 90% of astrocytoma present de novo as a glioblastoma. From the stage of glioblastoma occurrence, there is a poor survival rate, with a median of 16 months and survival rate of approximately 3% (5). It is extremely difficult to eliminate the glioblastoma even with total resection, as tumor cells persist microscopically, with tumor recurrence occurring in 90% of the patients at the original tumor location (6). The frequently seen extensive hypoxic regions in glioblastomas contribute to the highly malignant phenotype of these tumors, exacerbating the...
prognosis and clinical outcomes of the patients. Hypoxic tumor cells are more resistant to chemo- and radiation therapy (7,8) and are protected by the vasculature that develops due to hypoxia-mediated molecular processes (3). Hypoxia also supports the survival of neural and glioma stem cells, which are drug resistant and possess tumorigenicity potential (9,10). Considering the significance of hypoxia in the growth and aggressiveness of glioblastomas, targeting hypoxia potentially improves the outcomes in patients with this lethal cancer type.

2. Significance of hypoxia in development of glioblastoma

The pathognomonic feature of pseudopalisading necrosis, which is the area of hypercellularity surrounding necrotic regions, and vascular proliferation observed in glioblastoma tumors is a manifestation of hypoxia. These hypercellularity regions are highly hypoxic and represent tumor cells migrating away from vasoocclusive, distorted and degenerating blood vessels from the tumor center. Additionally, the cells have a high expression of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), which promote angiogenesis (11). A subset of growth factors including angiopoietins, fibroblast growth factors, chemokines and matrix metalloproteinases (MMPs) play an important role in tumor angiogenesis (12). These new vessels are deformed, leaky and have gaps between endothelial cells, resulting in vascular stasis. Repeated cycle of events of angiogenesis, vascular collapse due to deformation and cancer cell migration, contribute to rapid tumor expansion in adjacent normal tissue and invasion (13).

Inasmuch as hypoxia drives the progression and aggressiveness of glioblastoma tumors, a strategy for the treatment of this type of cancer has been developed by measuring tumor volume and the extent of intratumoral hypoxia, using fluoromisonidazole probe-based positron emission tomography, followed by appropriate targeting of hypoxic cells to improve the treatment outcome (14). As mentioned above, tumor stem cells residing in hypoxic pseudopalisading zones are protected from chemoradiation because of vascular stasis and depletion of molecular oxygen. In a prospective clinical trial testing bevacizumab and irinotecan in glioblastoma patients, it was observed that hypoxia-induced carbonic anhydrase (CA9) and HIF-2α were major and significant predictors of treatment effectiveness and overall survival (15).

3. Hypoxia, growth factors and tumor angiogenesis

Hypoxic response is essentially mediated by HIF-1α, which is induced under conditions of low oxygen, in a nuclear factor-xB-dependent manner. HIF-1α is a transcription factor that regulates the expression of approximately 60 genes involved in several cell pathways such as glycolysis, angiogenesis, invasion and epithelial-mesenchymal transition, which are critical for tumor growth and proliferation (Fig. 1). HIF-1α likely mediates the hypoxic response, partly through the upregulation of glucose transporter 1 (Glu1) and glycolytic genes, thereby promoting anaerobic glycolysis and metabolism to survive the unfavorable conditions encountered.
during hypoxia. Tumor initiating cancer stem cells undergo HIF-1α-mediated adaptation to hypoxia and thus have an elevated expression of various HIF-regulated genes (15). It has been shown that hypoxic area volume in the tumor is inversely proportional to the survival of the patients and thus hypoxic volume ratios greater than the median, survived only ~4 months as compared to >12 months in the patients with less than median hypoxic burden (14).

Multiple pro-angiogenic factors, which are under the regulation of HIF-1α and other transcription factors, are present in glioblastoma and contribute to the formation of new vessels (Fig. 1). VEGF, a prominent pro-angiogenic factor and its receptor VEGFR 2 (VEGFR2), are highly expressed in glioblastomas and tumor vasculature (17,18). In addition to angiogenesis, VEGF regulates vascular permeability and contributes to vasogenic edema. Most of the approaches developed for glioblastoma therapy that specifically address targeting angiogenesis, mainly focused on blocking VEGF signaling pathways (19). Primary glioblastomas also exhibit a high proportion of mutations and/or the overexpression of epidermal growth factor receptor (EGFR) gene. The EGFR gene codes for a 170-kDa receptor, which is a tyrosine kinase receptor, and a glycosylated plasma membrane. Altered EGFR function often leads to oncosenescence in various cell types and contributes to glioblastoma initiation, cancer cell proliferation and growth, invasion, resistance to apoptosis, chemoresistance, and radiotherapy and angiogenesis (20,21). It has been observed that almost 40% of glioblastomas have amplified EGFR gene expression with 50% of them showing overexpression of the receptor protein (22). Even in less malignant astrocytomas and oligodendrogliomas, there are elevated EGFR mRNA levels, suggesting that other oncogenic events play a role in the amplification of the EGFR gene (23).

Another important growth factor is transforming growth factor-β (TGF-β), whose signaling controls different cell functions such as proliferation, differentiation, and apoptosis and thus plays an important role in cancer progression, remodeling of the extracellular matrix and angiogenesis (24). The isoforms of TGF-β, TGF-β1/β2 and their complex cognate signaling machinery are known to be highly expressed in glioblastomas, and contribute to enhanced proliferation and invasion of tumor cells and tumor angiogenesis (25). TGF-β2 has been shown to contribute to aberrant vascular gene expression via Smad 2/4 and Smad 3/4 signaling pathways in glioblastoma (26). Experimental studies indicated that plate-derived growth factor (PDGF)-B overexpression in murine neural and glial progenitor cells leads to the formation of malignant gliomas (27), and it is known that human glioblastomas show elevated expression of PDGF and PDGF-receptor. PDGF-B, derived from tumor cells is shown to enhance angiogenesis in endothelial cells via increased production of VEGF (28). The net effect on overall angiogenesis in glioblastoma tumors is dependent on the source and availability of PDGF-B and the counteracting effects of Wnt/β-catenin signaling on angiogenesis (29).

### 4. Significance of abnormal vessel formation in glioblastoma

Glioblastomas are characterized by the presence of morphologically abnormal and dysfunctional vasculature, also known as glomeruloid bodies or vascular tufts (30). These glomeruloid bodies have multiple layers of endothelial cells, pericytes and smooth muscle cells and exhibit a thick basement membrane. Such morphology constitutes a typical diagnosis for glioblastoma, albeit not for low-grade gliomas (19). The origin of these vessels is not clear and controversial. Previous in vitro studies indicated that glioma stem-like cells can be induced to differentiate to an endothelial cell type and that glioblastoma stem-like cells contribute to vessel formation (Fig. 1) in experimental models (31,32). Although the blood-brain barrier, which consists of endothelial cells and pericytes astrocytes in normal brain vessels, is disrupted in glioblastoma, with a resultant increase in vascular permeability (33), this barrier appears to remain intact at the invasive front of the tumor and the normal cortex, which is invaded by migratory glioblastoma cells. Thus, therapeutic agents that target glioblastoma to cross the blood-brain barrier to attack the invasive glioblastoma cells. Of note, the malformed blood vessels in the glioblastoma tumors in turn contribute to increasing hypoxic conditions in the tumor, as these vessels are poorly perfused (34). As mentioned earlier, hypoxia is a potent inducer of tumor progression through metabolic reprogramming, resistance to cell death, immunosuppression, inflammation and epithelial-mesenchymal transition of cancer cells (13). The stabilized and thus elevated HIF-1α in glioma cells causes an increase in the expression of VEGF and CXC chemokine ligand 12, both of which promote angiogenesis through different mechanisms, eventually leading to the formation of the malformed vessels, thus leading to a vicious cycle that promotes glioblastoma tumor growth and aggressiveness (Fig. 1) (35).

### 5. Hypoxia and glioblastoma stem cells

Cancer stem cells are more potent in inducing tumors when injected into the brains of immunocompromised mice, as compared to non-stem cells from tumors. Cancer stem cells have a high level of resistance to radiation through activation of the DNA damage checkpoint and to chemoresistance (36,37). An important function of the tumor vasculature is to provide a supply of glioblastoma stem-like cells (38), which are critical for the progression of tumor growth and resistance to chemo- and radiotherapy. Notably, hypoxia is shown to increase the expression of CD133, a stem cell marker, in brain tumors and this increase is probably mediated by the HIF family of transcription factors (36,39). Of the HIF transcription factors, HIF-1α promotes proliferation and survival of all cancer cells and is activated in normal neural progenitors, thus limiting its value, in terms of therapeutic targeting. HIF-2α, which is practically absent in non-glioma stem cells, is specifically elevated in glioblastoma stem cells, even under modest hypoxic conditions, thereby making HIF-2α an interesting therapeutic target in glioblastomas (40). HIF-2α regulates chromatin structure by activating proteins/processes that modify chromatin epigenetically, such as the histone methyltransferase and mixed lineage leukemia 1 (41). Other hypoxia-induced genes, that are expressed at elevated levels in glioblastoma stem cells, include Oct4, Glut1, SerpinB9, and VEGF. In addition to
promoting angiogenesis by the glioma stem cells, hypoxia also increases other microenvironmental interactions by these cancer stem cells including the suppression of immune response. Hypoxia activates pSTAT signaling, thereby increasing the secretion of immunosuppressive cytokines such as CSF1 and CCL2, which are useful in inhibiting T-cell proliferation and macrophage phagocytosis, which in turn accelerate tumor progression (42).

Glioma stem cells show enhanced Notch signaling pathways (43,44), which contribute to their radioreistance (45). Thus, blocking Notch signaling in human glioblastoma stem cells with high doses of γ-secretase inhibitors reduces proliferation of these cancer stem cells and tumor formation, and increases differentiation (46). Other enhanced signaling pathways include PI3 kinase/Akt, Hedgehog and Stat3 (47-49).

6. Therapeutic implications

Inasmuch as hypoxia and hypoxia-induced factors promote the growth of glioblastomas, therapeutic measures addressing hypoxia have been developed. Thus, a monoclonal antibody against VEGF, bevacizumab, has been developed and approved as a second-line monotherapy of glioblastoma patients. However, bevacizumab therapy achieved improvement in progression-free survival but was not beneficial for overall survival (50). On the other hand, a subset of patients who positively responded to cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, which increased blood perfusion, showed improved survival (51). A better understanding of the significance and pathophysiology of tumor vasculature and associated factors is needed to develop effective therapeutics that target these elements of glioblastomas.

An interesting direct approach using a prodrug is via a hypoxia-activated TH-302, which is a nitroimidazole prodrug of bromo-isophosphoramide mustard (Br-IPM), a cytotoxin. Under hypoxic conditions, TH-302 is converted by intracellular reductases to the alkylating agent Br-IPM, which functions as a DNA cross-linking agent damaging the hypoxic tumor cells, in which it is formed. Br-IPM may also diffuse into the extracellular matrix and the nearby normoxic cells, showing its cytotoxic effects in these cells as well. However, TH-302 per se is not effective under normoxic conditions and requires hypoxic conditions to show its cytotoxic effects (52). A recent study showed that TH-302 is well tolerated when administered after a 4-week period of postsurgical recovery, to glioblastoma patients, in combination with bevacizumab (10 mg/kg), with a promising clinical benefit rate of 62% (53).

A major advance in the treatment of glioblastoma during the last decade is the concomitant chemoradiotherapy with temozolomide. It has been shown that the median survival of patients receiving radiation therapy alone is 12.1 months, whereas a combination of radiation with temozolomide increased the median survival to ≤14.6 months (54). One of 5 glioblastoma patients survived in the temozolomide-treated population, whereas essentially none of the patients without temozolomide survived to 3 years, during the follow-up. The survival promoting action of temozolomide is essentially due to the epigenetic modification of the methyl guanine methyl transferase (MGMT) promoter, in the glioblastoma cells, which leads to reduced or no expression of this enzyme and thus the inability to repair the guanine methylated induced by temozolomide. However, MGMT silencing by promoter modification is seen only in 40% of the glioblastoma cases. Therefore, the treatment benefit of temozolomide is not evident in the remaining 60% of the glioblastoma patients who harbor normal expression of the MGMT, which is capable of repairing the temozolomide-mediated guanine methylation (55).

Other agents that have been examined as therapeutic agents targeting HIFs are amphotericin B, an anti-fungal drug, which inhibits HIF-1α transcription (56); and 2-methoxyestradiol, an inhibitor of HIF-1α, which has been tested in phase-I clinical trials with some success showing stable disease in 38% of the enrolled patients (57). Despite the significant leaps in our understanding of the molecular events that underlie the aggressiveness and progression of glioblastomas, much progress is needed for effective therapeutic development that goes much further than extending life by a short period of time.

7. Conclusions

Among the CNS cancer grade IV astrocytomas, glioblastomas are highly aggressive. The extensive hypoxic regions in glioblastomas contribute to the highly malignant phenotype of these tumors, exacerbating the prognosis of the patients. Hypoxic tumor cells are resistant to chemo- and radiation therapy and are also protected by the dysfunctional vasculature that developed due to hypoxia. The abnormal and dysfunctional vessels play a critical role in generating pseudopalisading necrotic regions that are hypoxic and protect cancer stem cells residing in that region from therapeutic agents, which facilitates cancer stem cell proliferation and tumor growth, thus causing a vicious cycle of tumor growth. Therapeutic approaches that target hypoxia-induced factors such as use of monoclonal antibody against VEGF, bevacizumab, have been useful only in stabilizing the disease but failed to increase the overall survival. Hypoxia-activated TH-302 appears to be more attractive due to its better beneficial effects in glioblastoma patients. A better understanding of the hypoxia mediated protection of the glioblastoma cells is needed in future studies in order to develop more effective therapeutics.

References

1. Filippini G: Epidemiology of primary central nervous system tumors. Hand Clin Neurol 104: 3-22, 2012.
2. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, et al (eds): Seer cancer statistics review, 1975-2013. National Cancer Institute, Bethesda, MD. http://seer.Cancer.Gov/csr/1975_2013/ Accessed April 15, 2016.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al: Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007.
5. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 16 (Suppl 4): iv1-iv63, 2014.
transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGF-β in glioblastoma multiforme. Cancer Lett 232: 139-147, 2006.

Dieterich LC, Mellberg S, Langenkamp E, Zhang L, Zieba A, Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Massagué J: TGFβ in Cancer. Cell 134: 215-230, 2008.

Riddick G and Fine HA: Integration and analysis of genome-scale gene expression data from gliomas. Nat Rev Neurol 7: 439-450, 2011.

Dieterich LB, Langenkamp E, Zheng J, Zhang L, Zieba A, Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Massagué J: TGFβ in Cancer. Cell 134: 215-230, 2008.

Riddick G and Fine HA: Integration and analysis of genome-scale gene expression data from gliomas. Nat Rev Neurol 7: 439-450, 2011.

Dieterich LB, Langenkamp E, Zheng J, Zhang L, Zieba A, Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Massagué J: TGFβ in Cancer. Cell 134: 215-230, 2008.

Riddick G and Fine HA: Integration and analysis of genome-scale gene expression data from gliomas. Nat Rev Neurol 7: 439-450, 2011.

Dieterich LB, Langenkamp E, Zheng J, Zhang L, Zieba A, Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Massagué J: TGFβ in Cancer. Cell 134: 215-230, 2008.

Riddick G and Fine HA: Integration and analysis of genome-scale gene expression data from gliomas. Nat Rev Neurol 7: 439-450, 2011.

Dieterich LB, Langenkamp E, Zheng J, Zhang L, Zieba A, Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Massagué J: TGFβ in Cancer. Cell 134: 215-230, 2008.

Riddick G and Fine HA: Integration and analysis of genome-scale gene expression data from gliomas. Nat Rev Neurol 7: 439-450, 2011.

Dieterich LB, Langenkamp E, Zheng J, Zhang L, Zieba A, Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Massagué J: TGFβ in Cancer. Cell 134: 215-230, 2008.
49. Liu M, Inoue K, Leng T, Guo S and Xiong ZG: TRPM7 channels regulate glioma stem cell through STAT3 and Notch signaling pathways. Cell Signal 26: 2773-2781, 2014.

50. Keunen O, Johansson M, Oudin A, Sanze M, Rahim SA, Fack F, Thorsen F, Taux T, Bartos M, Jirik R, et al: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108: 3749-3754, 2011.

51. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, et al: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72: 402-407, 2012.

52. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, et al: Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 11: 740-751, 2012.

53. Cavazos DA and Brenner AJ: Hypoxia in astrocytic tumors and implications for therapy. Neurobiol Dis 5: 227-233, 2016.

54. Stupp R, Mason WP, van den Bent MJ, Weller M, Fischer B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.

55. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.

56. Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS and Park JW: Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107: 916-923, 2006.

57. Kirkpatrick J, Desjardins A, Quinn J, Rich J, Vredenburgh J, Sathornsumetee S, Gururangan S, Sidan C, Friedman H, Reardon D: Phase ii open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. J Clin Oncol (ASCO Annual Meeting abs.) 25: 2065, 2007.